Definitive Contract 75D30120C07637
Award Date 3/26/20
Potential Completion Date 6/30/21
Potential Value $4.8M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Nashville, TN 37232, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Vanderbilt University Medical Center was awarded a definitive cost-plus-fixed-fee contract valued at $14,222,774.34 by the Centers for Disease Control and Prevention under funding opportunity announcement topic 9.3. The prime contractor will lead a network of subcontractors to conduct a prospective cohort study to assess the effectiveness of COVID-19 and influenza vaccines in preventing virus transmission within households. Major subcontractors include the Universities of Arizona, Emory,...
- This is a $13,460,835.60 delivery order awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Vanderbilt University Medical Center. The contract is for an Adult Inpatient and Outpatient VE Case Control Study, which will evaluate the effectiveness of COVID-19 and influenza vaccines. This order falls under the larger Safety and Healthcare Epidemiology Prevention Research Development 2016 (SHEPheRD 2016) indefinite delivery/indefinite quantity...
- The Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) awarded a $1,906,532.45 firm fixed price contract to Vanderbilt University Medical Center (VUMC) to conduct the Influenza Vaccine Effectiveness in the CriticallY Ill (IVY) study. The IVY study is a multicenter prospective observational study focused on influenza infection among hospitalized adults, with a focus on critically ill patients in intensive care units. VUMC will serve as the Clinical...
- This firm fixed price contract from the Centers for Disease Control and Prevention (CDC) to Vanderbilt University Medical Center (VUMC) evaluates the effectiveness of vaccines against COVID-19, influenza, and respiratory syncytial virus (RSV) among U.S. adults with severe acute respiratory illness. The $11,908,903.84 potential value contract monitors effectiveness against COVID-19, influenza, and emerging variants, as well as duration of protection. It also conducts RSV surveillance and builds...
- This is a prime contract award from the Centers for Disease Control and Prevention (CDC) to Vanderbilt University Medical Center (VUMC), a leading academic medical center and nonprofit healthcare provider. The $33,581,705.97 fixed-price contract, awarded under the CDC's Fiscal Year 2021 Broad Agency Announcement, supports VUMC's research on topics related to Topic 9.1. The contract has no set-aside designation. VUMC is a major recipient of federal funding and has extensive experience managing...
- This is a $12,797,150.73 Definitive Contract awarded by the Centers for Disease Control and Prevention (CDC) to Vanderbilt University Medical Center (VUMC), a major academic medical center and nonprofit healthcare provider, for a new network of household transmission studies to evaluate vaccine effectiveness. The contract has a performance period ending on March 28, 2025 and utilizes a Firm Fixed Price pricing arrangement. VUMC is serving as the prime contractor and has awarded subcontracts to...
- This federal contract award was issued by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to Vanderbilt University Medical Center (VUMC) to conduct a Phase II vaccine trial for Influenza H7N9. The contract has a total potential value of $4,033,051 and a completion date of May 31, 2021. This award is part of the Vaccine and Treatment Evaluation Units (VTEU) program, a major program focused on vaccine development and...
- This is a firm fixed-price federal contract award to Vanderbilt University Medical Center (VUMC), a non-profit healthcare provider in Nashville, Tennessee. The contract was awarded by the Centers for Disease Control and Prevention (CDC) on December 18, 2020 for $3,749,778.73 to support COVID-19 host pathogen discovery research under the CDC's Broad Agency Announcement (BAA) program. The contract has a period of performance through November 29, 2022. VUMC, which has a long history of federal...
- This federal contract award, valued at $1,072,649.00, was issued by the Centers for Disease Control and Prevention (CDC) to The Vanderbilt University, a leading private research institution. The contract is a delivery order under the Clinical Immunization Safety Assessment (CISA) indefinite delivery vehicle, which supports the CDC's efforts to conduct research and analysis related to vaccine safety. The award does not have a set-aside designation, reflecting Vanderbilt's status as a large...
- This federal contract award, valued at $7,415,829.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (DHHS), to Vanderbilt University Medical Center (VUMC) to support research on the "Genetic and Structural Basis for Virus Neutralization". The original solicitation, a pre-solicitation notice, indicates that NIAID is seeking research to enhance the...